Plain-English translation of NCT06059144 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called norepinephrine can help protect your brain after a specific type of stroke called a perforating artery stroke. The medication works by raising your blood pressure in a controlled way, which may help restore blood flow to the parts of your brain that aren't getting enough oxygen. Researchers believe this could prevent your stroke symptoms from worsening in the hours or days after the stroke happens.
About 1 in 4 ischemic strokes happen in small blood vessels called perforating arteries, and many people experience worsening symptoms within the first few days. Because these small vessels have limited backup blood supplies, raising blood pressure with medication might help get blood flowing to the affected brain tissue before permanent damage occurs.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive the medication through an IV line while your blood pressure is monitored closely in the hospital. The medication will be adjusted to keep your blood pressure in a safe target range, and after 24 hours of stable symptoms, the medication will be gradually decreased and stopped. You will be monitored with standard stroke care, and your neurological condition will be assessed regularly to see how you are recovering.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
France
Phase
Large-scale testing
Sponsor
University Hospital, Bordeaux
Enrollment target
~358 participants
Started
November 2024
Primary completion
August 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Pauline RENOU
University Hospital, Bordeaux
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.